151 related articles for article (PubMed ID: 31192543)
1. Preclinical evaluation of an unconventional ruthenium-gold-based chemotherapeutic: RANCE-1, in clear cell renal cell carcinoma.
Elie BT; Hubbard K; Pechenyy Y; Layek B; Prabha S; Contel M
Cancer Med; 2019 Aug; 8(9):4304-4314. PubMed ID: 31192543
[TBL] [Abstract][Full Text] [Related]
2. A heterometallic ruthenium-gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer.
Elie BT; Pechenyy Y; Uddin F; Contel M
J Biol Inorg Chem; 2018 May; 23(3):399-411. PubMed ID: 29508136
[TBL] [Abstract][Full Text] [Related]
3. Auranofin-Based Analogues Are Effective Against Clear Cell Renal Carcinoma
Elie BT; Hubbard K; Layek B; Yang WS; Prabha S; Ramos JW; Contel M
ACS Pharmacol Transl Sci; 2020 Aug; 3(4):644-654. PubMed ID: 32832867
[TBL] [Abstract][Full Text] [Related]
4. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
[TBL] [Abstract][Full Text] [Related]
5. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.
Sinha S; Dwivedi N; Tao S; Jamadar A; Kakade VR; Neil MO; Weiss RH; Enders J; Calvet JP; Thomas SM; Rao R
Oncogene; 2020 Feb; 39(6):1231-1245. PubMed ID: 31616061
[TBL] [Abstract][Full Text] [Related]
6. Traditional Chinese medicine Bu-Shen-Jian-Pi-Fang attenuates glycolysis and immune escape in clear cell renal cell carcinoma: results based on network pharmacology.
Zheng J; Xu W; Liu W; Tang H; Lu J; Yu K; Song X; Li F; Wang Y; Wang R; Chen L; Zhang H; Qiu Y; Wei G; Zhou X; Yang J
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34002799
[TBL] [Abstract][Full Text] [Related]
7. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
9. KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2.
Cocco E; Leo M; Canzonetta C; Di Vito S; Mai A; Rotili D; Di Napoli A; Vecchione A; De Nunzio C; Filetici P; Stoppacciaro A
Clin Epigenetics; 2018; 10():44. PubMed ID: 29632619
[TBL] [Abstract][Full Text] [Related]
10. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
11. Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer.
Elie BT; Fernández-Gallardo J; Curado N; Cornejo MA; Ramos JW; Contel M
Eur J Med Chem; 2019 Jan; 161():310-322. PubMed ID: 30368130
[TBL] [Abstract][Full Text] [Related]
12. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
13. PTPN3 Inhibits the Growth and Metastasis of Clear Cell Renal Cell Carcinoma via Inhibition of PI3K/AKT Signaling.
Peng XS; Yang JP; Qiang YY; Sun R; Cao Y; Zheng LS; Peng LX; Lang YH; Mei Y; Li CZ; Meng DF; Liu ZJ; Wang MD; Zhou FJ; Huang BJ; Qian CN
Mol Cancer Res; 2020 Jun; 18(6):903-912. PubMed ID: 32169891
[TBL] [Abstract][Full Text] [Related]
14. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
[TBL] [Abstract][Full Text] [Related]
15. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
[TBL] [Abstract][Full Text] [Related]
16. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
Yoshino H; Yamada Y; Enokida H; Osako Y; Tsuruda M; Kuroshima K; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M
PLoS One; 2020; 15(7):e0236119. PubMed ID: 32667929
[TBL] [Abstract][Full Text] [Related]
17. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
18. Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines.
Pasha M; Sivaraman SK; Frantz R; Agouni A; Munusamy S
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30909494
[TBL] [Abstract][Full Text] [Related]
19. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
Wang L; Park P; La Marca F; Than KD; Lin CY
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1013-24. PubMed ID: 25431339
[TBL] [Abstract][Full Text] [Related]
20. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
Dong Y; Manley BJ; Becerra MF; Redzematovic A; Casuscelli J; Tennenbaum DM; Reznik E; Han S; Benfante N; Chen YB; Arcila ME; Aras O; Voss MH; Feldman DR; Motzer RJ; Fabbri N; Healey JH; Boland PJ; Chawla M; Durack JC; Lee CH; Coleman JA; Russo P; Hakimi AA; Cheng EH; Hsieh JJ
Eur Urol Focus; 2017 Dec; 3(6):590-598. PubMed ID: 28753786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
